Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $182.06, representing a 48.4% upside. In a report issued on December 19, Mizuho Securities also maintained a Buy rating on the stock with a $200.0...
SRPT Stock USD 103.06 3.80 3.56% Sarepta Therapeutics volume indicators tool provides the execution environment for running the Chaikin AD Line indicator and other technical functions against Sarepta Therapeutics. Sarepta Therapeutics value trend is the prevailing direction of the price over some defined ...